Latest filing published 23 Jun 2022 for Cullinan Oncology, Inc., €271k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
F2 Bioscience I 2017 Ltd: trading record in brief
This profile gathers the share dealings of F2 Bioscience I 2017 Ltd in Cullinan Therapeutics, Inc. In total, 3 filings cover trades dated from 21 June 2022 to 23 June 2022.
On the market, this insider has only sold: 3 sales, €1.2M in total.
The newest entry dates from 23 June 2022: an open-market sale of €601k, in Cullinan Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to F2 Bioscience I 2017 Ltd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 22,319 shares@ US$12.76620.028% mcap100.0% of flowCommon StockSEC:0001104659-22-073980:0
1 of 1 declaration
